Jade Biosciences Q3 net loss widens less than expected

By Reuters News


Overview

  • US biotech firm's Q3 net loss widened, but beat analyst expectations

  • R&D and G&A expenses rose yr/yr, increasing total operating expenses

  • Company ended Q3 with $475.7 mln in cash and investments, expects runway into Q4 2028


Outlook

  • Company expects to initiate Phase 3 EVERGREEN trial in IgA nephropathy in Q4 2026

  • Interim data from Phase 2 JUNIPER trial in IgA nephropathy expected in Q2 2027

  • Cash, cash equivalents and investments expected to provide runway into Q4 2028


Result Drivers

  • R&D SPENDING - R&D expenses rose due to increased costs for chemistry, manufacturing, controls, clinical activity, and personnel-related costs, including stock-based compensation

  • G&A COSTS - G&A expenses increased due to higher personnel-related costs and stock-based compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Loss

Beat

$35.1 mln

$50.52 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Jade Biosciences, Inc. is $47.00, about 196.2% above its November 12 closing price of $15.87


Reuters Recommended Reads

  • Nov 12 - Prime Medicine Q3 loss narrows as expenses decline

  • Nov 12 - Pliant Therapeutics Q3 net loss narrows on lower expenses

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk